Table 2.

Association between fibrosis risk groups, defined based on FIB-4 values at baseline and 3-year landmark time and subsequent risk of developing HCC.

Baseline	3-year landmark	n (%)a	HCC events	HCC incidence per 1,000 PY (95% CI)b
Overall cohort		202,319	473	0.28 (0.27,0.30)
Low risk n = 151,194	Low risk	119,547 (79.1)	56	0.05 (0.04–0.07)
	Indeterminate risk	29,542 (19.5)	50	0.21 (0.16–0.28)
	High risk	2,105 (1.4)	11	0.76 (0.38–1.37)
Indeterminate risk n = 43,341	Low risk	9,729 (22.4)	20	0.26 (0.16–0.40)
	Indeterminate risk	26,581 (61.3)	109	0.53 (0.43–0.64)
	High risk	7,031 (16.2)	90	1.90 (1.52–2.33)
High riskd n = 7,784	Low/indeterminate risk	3,483 (44.7)	21	0.86 (0.53–1.31)
	High risk	4,301 (55.3)	116	4.56 (3.77–5.47)
Baselinec	3-year landmark	n (%)a	Cirrhosis or HCC eventsa	Cirrhosis or HCC incidence per 1,000 PY (95% CI)b
Overall cohort		201,224	2,161	1.31 (1.25–1.37)
Low risk n = 150,911	Low risk	119,401 (79.1)	416	0.41 (0.37–0.45)
	Indeterminate risk	29,435 (19.5)	317	1.34 (1.19–1.49)
	High risk	2,075 (1.4)	119	8.59 (7.11–10.28)
Indeterminate risk n = 42,996	Low risk	9,672 (22.5)	96	1.25 (1.01–1.52)
	Indeterminate risk	26,456 (61.5)	453	2.22 (2.02–2.44)
	High risk	6,868 (16.0)	358	7.87 (7.07–8.73)
High riskd n = 7,317	Low/indeterminate risk	3,407 (46.6)	73	3.06 (2.40–3.85)
	High risk	3,910 (53.4)	329	14.25 (12.76–15.89)

FIB-4, fibrosis-4; HCC, hepatocellular carcinoma; PY, person years.

^aPercentage (%) calculated with number within FIB-4 group at baseline as the denominator.

^bIncidence rate calculated using imputed data.

^cExcluded patients who developed composite outcome (cirrhosis or HCC) prior to 3-year landmark time.

^dData from high to low and indeterminate risk were combined due low number of patients and events in high to low-risk group.